GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » WuXi Biologics (Cayman) Inc (FRA:1FW2) » Definitions » Price-to-Owner-Earnings

WuXi Biologics (Cayman) (FRA:1FW2) Price-to-Owner-Earnings : 54.67 (As of Apr. 28, 2024)


View and export this data going back to 2017. Start your Free Trial

What is WuXi Biologics (Cayman) Price-to-Owner-Earnings?

As of today (2024-04-28), WuXi Biologics (Cayman)'s share price is €1.6402. WuXi Biologics (Cayman)'s Owner Earnings per Share (TTM) ended in Dec. 2023 was €0.03. It's Price-to-Owner-Earnings for today is 54.67.


The historical rank and industry rank for WuXi Biologics (Cayman)'s Price-to-Owner-Earnings or its related term are showing as below:

FRA:1FW2' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 53.25   Med: 358.15   Max: 1070.97
Current: 62.41

During the past 10 years, the highest Price-to-Owner-Earnings of WuXi Biologics (Cayman) was 1070.97. The lowest was 53.25. And the median was 358.15.


FRA:1FW2's Price-to-Owner-Earnings is ranked worse than
69.59% of 171 companies
in the Biotechnology industry
Industry Median: 31.62 vs FRA:1FW2: 62.41

As of today (2024-04-28), WuXi Biologics (Cayman)'s share price is €1.6402. WuXi Biologics (Cayman)'s Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was €0.10. Therefore, WuXi Biologics (Cayman)'s PE Ratio for today is 16.57.

As of today (2024-04-28), WuXi Biologics (Cayman)'s share price is €1.6402. WuXi Biologics (Cayman)'s EPS without NRI for the trailing twelve months (TTM) ended in was €0.12. Therefore, WuXi Biologics (Cayman)'s PE Ratio without NRI for today is 14.02.

During the past 10 years, WuXi Biologics (Cayman)'s highest PE Ratio without NRI was 292.80. The lowest was 10.00. And the median was 122.69.


WuXi Biologics (Cayman) Price-to-Owner-Earnings Historical Data

The historical data trend for WuXi Biologics (Cayman)'s Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WuXi Biologics (Cayman) Price-to-Owner-Earnings Chart

WuXi Biologics (Cayman) Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 377.00 532.50 497.50 239.90 -

WuXi Biologics (Cayman) Semi-Annual Data
Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 497.50 - 239.90 - -

Competitive Comparison of WuXi Biologics (Cayman)'s Price-to-Owner-Earnings

For the Biotechnology subindustry, WuXi Biologics (Cayman)'s Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


WuXi Biologics (Cayman)'s Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, WuXi Biologics (Cayman)'s Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where WuXi Biologics (Cayman)'s Price-to-Owner-Earnings falls into.



WuXi Biologics (Cayman) Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

WuXi Biologics (Cayman)'s Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=1.6402/0.03
=54.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


WuXi Biologics (Cayman)  (FRA:1FW2) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


WuXi Biologics (Cayman) Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of WuXi Biologics (Cayman)'s Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


WuXi Biologics (Cayman) (FRA:1FW2) Business Description

Address
No. 108, Meiliang Road, Mashan Binhu District, Wuxi, CHN, 214092
WuXi Biologics is one of the largest global biologics CRDMOs. WuXi Biologics, incorporated in 2014 following the reorganization of WuXi PharmaTech, later known as WuXi AppTec, now has global revenue of CNY 15 billion. North American represented 55.6% of total revenue in 2022. It adopts the follow and win the molecule strategy by providing end-to-end services, from drug discovery to commercial manufacturing. It also adopts a global dual-sourcing strategy by providing drug products and large-scale drug substance manufacturing.

WuXi Biologics (Cayman) (FRA:1FW2) Headlines

No Headlines